Response of vulvar lichen sclerosus and squamous cell hyperplasia to graduated topical steroids.

Abstract

OBJECTIVE:

To determine whether symptomatic remission could be obtained equally effectively in patients with vulvar lichen sclerosus, squamous cell hyperplasia or mixed disease in response to a standardized course of graduated topical steroids.

STUDY DESIGN:

A retrospective analysis of 137 patients with biopsy-proven lichen sclerosus (84), squamous cell hyperplasia (42) or mixed disease (11) treated between 1990 and 1997 with a standard, three-month regimen of graduated topical steroids was carried out. Presence or absence of symptoms and side effects of treatment were recorded three and six months following induction of the initial graduated topical steroid regimen.

RESULTS:

On completion of the graduated topical steroid course, 59% of patients were asymptomatic (P = .035), and at six months, 58% were asymptomatic (P = .11). Remission of symptoms was more easily achieved in patients with lichen sclerosus as compared to patients with squamous cell hyperplasia and mixed disease at both three and six months (P = .09 at three and P = .035 at six). Four cases of local reactions to the steroids were recorded, as were two cases of vulvar malignancy.

CONCLUSION:

Symptomatic remission was significantly easier to achieve in patients with vulvar lichen sclerosus as compared to those with squamous cell hyperplasia following treatment with graduated topical steroids.

• Authors: T J Clark, I J Etherington, D M Luesley
• Journal: The Journal of reproductive medicine (J Reprod Med) Vol. 44 Issue 11 Pg. 958-62 (Nov 1999) ISSN: 0024-7758 [Print] United States
• PMID: 10589407 (Publication Type: Journal Article)

Chemical References

• Steroids

Topics

• Administration, Topical
• Dose-Response Relationship, Drug
• Epithelial Cells
• Female
• Humans
• Hyperplasia (drug therapy)
• Lichen Sclerosus et Atrophicus (drug therapy, pathology)
• Middle Aged
• Retrospective Studies
• Steroids (administration & dosage, therapeutic use)
• Treatment Outcome
• Vulvar Diseases (drug therapy, pathology)